← Back to Search

Monoclonal Antibodies

Bimekizumab for Axial Spondyloarthritis (BE MOBILE 1 Trial)

Phase 3
Waitlist Available
Research Sponsored by UCB Biopharma SRL
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline (day 1) until safety-follow-up (up to week 72)
Awards & highlights

BE MOBILE 1 Trial Summary

This trial is testing whether a new drug, bimekizumab, is effective, safe, and tolerable for treating active nonradiographic axial spondyloarthritis.

Eligible Conditions
  • Non-radiographic Axial Spondyloarthritis

BE MOBILE 1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline (day 1) until safety-follow-up (up to week 72)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline (day 1) until safety-follow-up (up to week 72) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Spondylarthritis
Secondary outcome measures
Ankylosing spondylitis
Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 16
Assessment of SpondyloArthritis International Society (ASAS) partial remission (PR) at Week 16
+13 more

BE MOBILE 1 Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: BimekizumabExperimental Treatment1 Intervention
Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.
Group II: PlaceboPlacebo Group2 Interventions
Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bimekizumab
2018
Completed Phase 3
~6510

Find a Location

Who is running the clinical trial?

UCB Biopharma SRLLead Sponsor
101 Previous Clinical Trials
21,196 Total Patients Enrolled
3 Trials studying Axial Spondyloarthritis
619 Patients Enrolled for Axial Spondyloarthritis
UCB CaresStudy Director001 844 599 2273
205 Previous Clinical Trials
44,723 Total Patients Enrolled
9 Trials studying Axial Spondyloarthritis
2,407 Patients Enrolled for Axial Spondyloarthritis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are some possible dangers associated with Bimekizumab?

"There is evidence from past clinical trials to support the safety of Bimekizumab, giving it a score of 3."

Answered by AI

How many individuals are being observed in this experiment?

"Unfortunately, this study is no longer looking for patients. The trial was initially posted on April 25th, 2019 and updated for the last time on October 25th, 2022. There are other trials you could look into; as of right now, there are 69 clinical trials concerning spondylarthritis and 8 studies involving Bimekizumab that are actively enrolling patients."

Answered by AI

Do you have any open slots for new participants in this research?

"This study is not searching for participants at the moment. The trial was originally posted on 4/25/2019 and was last edited on 10/25/2022. However, if you are looking for other studies, there are currently 69 trials actively admitting participants with spondylarthritis and 8 studies for Bimekizumab that are actively searching for participants."

Answered by AI

Has a similar study been conducted before?

"Currently, there are 8 ongoing clinical trials for Bimekizumab spanning 120 cities and 26 countries. The first study was conducted in 2018 by UCB Biopharma SRL. This Phase 3 trial included 743 patients and completed drug approval in 2018. Since then, 18296 studies have been completed."

Answered by AI

What are some other ways that Bimekizumab has been studied?

"There are seven Phase 3 clinical trials and one Phase 4 clinical trial researching Bimekizumab currently underway. Many of these studies are based in Phillip, Oregon; however, there are 1,025 total locations where research is being conducted."

Answered by AI

Who else is applying?

What state do they live in?
Minnesota
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis
2019. "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03928704.
~41 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top